Coya Therapeutics Inc. (NASDAQ: COYA) witnessed a 9% increase in its share value after securing $10 million through a private placement. The biotechnology firm, specializing in developing therapies targeting regulatory T cells (Tregs), issued 1.4 million common shares at $7.25 each. The transaction drew significant interest from institutional and accredited investors, reflecting confidence in Coya’s […]
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking a significant advancement in the treatment of neurodegenerative diseases. This collaboration focuses on the development of COYA 302, a dual biologic designed to combat neuroinflammation and treat various neurodegenerative conditions. […]
